Decibel Therapeutics Inc DBTX Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Feb 19, 2021 (filed on Feb 19, 2021)

Insider Name:

Exter Neil

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3/A : Amendment of a previous Form 3

# or value acquired/disposed of:

--

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Series D Preferred Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

-1,737,619

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Series C Preferred Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

-3,125,000

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Series A Preferred Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

-7,119,850

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

150,000

Price:

$18.00
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

327,852

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

247,324

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

458,487

Price:

--
Feb 17, 2021 (filed on Feb 18, 2021)

Insider Name:

Longevity Fund 2 LP

Ownership Type:

Direct Ownership

Securities:

Convertible Series C Preferred Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

-79,143

Price:

--
Feb 17, 2021 (filed on Feb 18, 2021)

Insider Name:

Longevity Fund 2 LP

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

79,143

Price:

--

Filings by filing date

Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Series D Preferred Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

-1,737,619

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Series C Preferred Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

-3,125,000

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Series A Preferred Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

-7,119,850

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

150,000

Price:

$18.00
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

327,852

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

247,324

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Glaxosmithkline Plc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

458,487

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Orbimed Advisors Llc

Ownership Type:

Indirect Ownership

Securities:

Series D Preferred Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

-1,158,412

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Orbimed Advisors Llc

Ownership Type:

Indirect Ownership

Securities:

Series D Preferred Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

-1,737,619

Price:

--
Feb 17, 2021 (filed on Feb 19, 2021)

Insider Name:

Orbimed Advisors Llc

Ownership Type:

Indirect Ownership

Securities:

Series D Preferred Stock

Nature of Transaction:

C - Conversion

# or value acquired/disposed of:

-14,480,162

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	1325 Boylston Street, Suite 500 BOSTON MA 02215
Tel:	N/A
Website:	https://www.decibeltx.com
IR:	See website

Key People

Laurence E. Reid Chief Executive Officer, Director	Gabriel Corfas Founder	M. Charles Liberman Founder
Ulrich Mueller Founder	Elisabeth Leiderman Chief Financial Officer

Business Overview

Decibel Therapeutics Inc is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorders. The Company is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company's pipeline product includes its gene therapy program (DB-OTO) to treat congenital monogenic deafness and its ototoxicity prevention program. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.

Financial Overview

For the nine months ended 30 September 2020, DecibelTherapeutics Inc revenues was not reported. Net lossapplicable to common stockholders decreased 22% to $34.7M.Lower net loss reflects R&D bal decrease of 44% to $14.4M(expense), General and administrative - Bal decrease of 27%to $8.1M (expense), Stock-based Compensation in R&Ddecrease of 15% to $352K (expense).

Employees:	37 as of Dec 31, 2020

Reporting Currency:	U.S. Dollars
Enterprise value:	$489.19M as of Sep 30, 2020
Annual revenue (TTM):	$0.00M as of Sep 30, 2020
EBITDA (TTM):	-$27.67M as of Sep 30, 2020
Net annual income (TTM):	-$43.73M as of Sep 30, 2020
Free cash flow (TTM):	-$38.35M as of Sep 30, 2020
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	24,217,428 as of Feb 12, 2021
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Decibel Therapeutics Inc (OQ:DBTX)